Key result
Administration of desvenlafaxine precipitated neuroleptic malignant syndrome in a patient with resistant schizophrenia who was on clozapine.
Case Report (n=1)
This case report highlights the potential for desvenlafaxine to precipitate neuroleptic malignant syndrome, possibly through an idiosyncratic interaction with clozapine.
Clinicians should monitor for NMS with desvenlafaxine added to clozapine; single case leaves open causality and generalizability.
Neuroleptic malignant syndrome is a rare and potentially serious syndrome associated with the use of many antipsychotic, antiparkinsonian, antidepressants, etc. Moreover, of the agents known to cause this entity, clozapine has been mentioned a fewer times, but desvenlafaxine has never been known to precipitate it. However in this study, we present a case of established Neuroleptic syndrome that precipitated after administration of desvenlafaxine in a patient of resistant schizophrenia who was on clozapine. The presenting case explores the possibility of the potential of desvenlafaxine in causing this rare clinical entity and also a possible idiosyncratic interaction between desvenlafaxine and clozapine, whose mechanism is yet to be known.
No takes yet. Share an insight, caveat, or question.
Chakraborty et al. (2011) conducted a case report in Resistant schizophrenia (n=1). Desvenlafaxine was evaluated on Neuroleptic malignant syndrome. Administration of desvenlafaxine precipitated neuroleptic malignant syndrome in a patient with resistant schizophrenia who was on clozapine.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: